x

Search for a networks

* (*) mandatory field

ZEPHYR: A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analog, on Food-related Behaviors in Patients With Prader-Willi Syndrome

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : -
  • Sponsor : MILLENDO THERAPEUTICS SAS
  • Website
  • Coordinator of multinational clinical trial

  • INFORMATION NOT PROVIDED
  • Millendo Therapeutics Ltd
  • Suite 1, 3rd Floor, 11-12 St. James's Square
  • LONDON SW1Y 4LB
  • UNITED KINGDOM
  • More information
  • Phone  : -
  • Fax  : -
  • Website
  • Contact secretary  :
Last update: March 2020

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.